Results 131 to 140 of about 919,252 (159)

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib. [PDF]

open access: yesSignal Transduct Target Ther
Shi Y   +15 more
europepmc   +1 more source

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS). [PDF]

open access: yesNat Commun
Li A   +15 more
europepmc   +1 more source

TAVR for Pure Aortic Regurgitation: A Patient-Specific Simulation-Based Feasibility Study. [PDF]

open access: yesJACC Asia
Mao Y   +8 more
europepmc   +1 more source

MICA-129 Met/Met contributes to the susceptibility of colorectal cancer. [PDF]

open access: yesMedicine (Baltimore)
Ye J, Chang R, Zhang J, Qian F, Ding W.
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Drivers and impacts of changes in China’s drylands

Nature Reviews Earth & Environment, 2021
Changjia Li, 伯杰 傅, Shuai Wang
exaly  

Home - About - Disclaimer - Privacy